Royalty Pharma plc
General ticker "RPRX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $19.4B (TTM average)
Royalty Pharma plc follows the US Stock Market performance with the rate: 49.3%.
Estimated limits based on current volatility of 1.6%: low 58.62$, high 60.55$
Factors to consider:
- Company pays dividends (quarterly): last record date 2026-08-14, amount 0.23$ (Y1.51%)
- Total employees count: 100 (+1.0%) as of 2025
- Top business risk factors: Royalty payment cessation, Acquisition/divestiture risks, Operational and conduct risks, Assumptions underlying business model incorrect, Leverage exacerbating losses
- Current price 26.2% above estimated high
- Earnings for 6 months up through Q2 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [32.65$, 48.29$]
- 2026-12-31 to 2027-12-31 estimated range: [32.93$, 48.93$]
Financial Metrics affecting the RPRX estimates:
- Positive: with PPE of 8.1 at the end of fiscal year the price was neutral
- Positive: Operating profit margin, % of 65.58 > 33.79
- Positive: 11.37 < Operating cash flow per share per price, % of 14.76
- Positive: 5.14 < Return on assets ratio (scaled to [-100,100]) of 6.32
- Positive: -11.23 < Investing cash flow per share per price, % of -9.57
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Inventory ratio change, % of 0 <= 0
- Positive: Interest expense per share per price, % of 1.82 <= 2.54
Short-term RPRX quotes
Long-term RPRX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $2,354.55MM | $2,263.58MM | $2,378.19MM |
| Operating Expenses | $862.40MM | $971.13MM | $818.67MM |
| Operating Income | $1,492.15MM | $1,292.44MM | $1,559.52MM |
| Non-Operating Income | $207.94MM | $38.37MM | $-235.33MM |
| Interest Expense | $187.19MM | $225.51MM | $307.66MM |
| R&D Expense | $52.00MM | $2.00MM | $452.00MM |
| Income(Loss) | $1,700.09MM | $1,330.81MM | $1,324.19MM |
| Net Income(Loss)* | $1,134.83MM | $858.98MM | $770.95MM |
| Stockholders Equity | $10,084.29MM | $10,342.37MM | $9,714.94MM |
| Assets | $16,381.85MM | $18,222.72MM | $19,620.78MM |
| Operating Cash Flow | $2,987.80MM | $2,768.99MM | $2,489.82MM |
| Investing Cash Flow | $-2,072.79MM | $-2,678.11MM | $-1,614.18MM |
| Financing Cash Flow | $-2,148.75MM | $361.14MM | $-1,185.97MM |
| Earnings Per Share** | $2.54 | $1.93 | $1.79 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.